Lena M. Kranz

Messenger RNA delivery of a dual CD25/CD122 affinity-tuned IL-2 variant prolongs exposure and potentiates antitumor T cell immunity

Mathias Vormehr, Lena M. Kranz, Alexander Muik, Sina Fellermeier-Kopf et autres

The therapeutic potential of interleukin-2 (IL-2) in cancer treatment is limited by toxicity challenges, partly due to an unfavorable pharmacokinetic profile and unintended activation of regulatory T (T reg ) cells alongside the desired activation of CD8 + effector T cells. To …

de (code pays fourni par la source)

Figure S7 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity

Daniel Peters, Lena M. Kranz, David Eisel, Mustafa Diken et autres

Gating strategy for antigen-specific CD8+ T cells, Tregs, and NK cells displayed in Figure 6.

Figure S4 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity

Daniel Peters, Lena M. Kranz, David Eisel, Mustafa Diken et autres

Antitumor immunity in response to RNA-LPX and Alb-IL2 RNA-NP. Absolute number of vaccine antigen-specific and nonvaccine antigen-specific CD8+ T cells, Tregs, and NK cells in the tumor (n=6 mice/group; A), tumor-draining lymph node (n=6 mice/group; B), and spleen (Alb RNA-NP: n=5 mice/group; …

Figure S3 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity

Daniel Peters, Lena M. Kranz, David Eisel, Mustafa Diken et autres

Expansion of Tregs in response to RNA-LPX and Alb-IL2 RNA-NP. Number of regulatory CD4+ T cells per spleen 7 days after the last of three weekly i.v. vaccinations with gp70 RNA-LPX (A) or OVA RNA-LPX (B) combined with Alb-IL2 RNA-NP or Alb …

Figure S8 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity

Daniel Peters, Lena M. Kranz, David Eisel, Mustafa Diken et autres

Representative dot plots and histograms corresponding to flow cytometry data displayed in Figure 3.

Figure S5 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity

Daniel Peters, Lena M. Kranz, David Eisel, Mustafa Diken et autres

Gating strategy for antigen-specific CD8+ T cells and Tregs in the blood.

Figure S6 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity

Daniel Peters, Lena M. Kranz, David Eisel, Mustafa Diken et autres

Gating strategy for antigen-specific CD8+ T cells in the spleen.

Figure S10 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity

Daniel Peters, Lena M. Kranz, David Eisel, Mustafa Diken et autres

Representative dot plots corresponding to flow cytometry data displayed in Figure 5.

Figure S11 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity

Daniel Peters, Lena M. Kranz, David Eisel, Mustafa Diken et autres

Representative dot plots corresponding to flow cytometry data displayed in Figure 6.

Figure S9 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity

Daniel Peters, Lena M. Kranz, David Eisel, Mustafa Diken et autres

Representative dot plots corresponding to flow cytometry data displayed in Figure 4.

Figure S1 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity

Daniel Peters, Lena M. Kranz, David Eisel, Mustafa Diken et autres

Mouse body weight in response to RNA-LPX and Alb-IL2 RNA-NP or rIL-2. Mouse total body weight after each of three weekly i.v. vaccinations with OVA RNA-LPX combined with one (1x) or five (5x) i.p. injections of rIL-2 or one i.v. injection of …

Figure S2 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity

Daniel Peters, Lena M. Kranz, David Eisel, Mustafa Diken et autres

Expansion of nonvaccine antigen-specific CD8+ T cells in response to RNA-LPX and Alb-IL2 RNA-NP. Number of nonvaccine antigen-specific CD8+ T cells per spleen (gp70 (A), OVA (B)) or per 4 x 106 splenocytes (TRP-1 (C)) 7 days after the last of three …